Shopping Cart
Remove All
Your shopping cart is currently empty
Suciraslimab (SM03) is a human IgG1 monoclonal antibody against the B-cell restriction antigen CD22 for the treatment of rheumatoid arthritis (RA) and other B-cell related diseases.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $619 | - | In Stock | |
| 10 mg | $953 | - | In Stock | |
| 25 mg | $1,390 | - | In Stock | |
| 50 mg | $1,880 | - | In Stock |
| Description | Suciraslimab (SM03) is a human IgG1 monoclonal antibody against the B-cell restriction antigen CD22 for the treatment of rheumatoid arthritis (RA) and other B-cell related diseases. |
| In vivo | In 5xFAD Alzheimer's disease mouse models, intraperitoneal injection of Suciraslimab (10 mg/kg, once weekly for 4 weeks) significantly enhanced microglial metabolic activity and phagocytosis, reduced brain amyloid plaque burden, and upregulated neuroprotective gene expression[1]. |
| Synonyms | SM03, SM 03 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2415439-63-1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.